17. Cash-settled share-based payment arrangements
 
  Group Company
R'000 2024 2023 2024 2023
Cash-settled share-based payment liability
Balance at the beginning of the year 21 298 20 312 21 298 20 312
Share-based payment expense* 14 624 11 115 14 624 11 115
Share grants vested and paid (15 283) (10 129) (15 283) (10 129)
Balance at the end of the year 20 639 21 298 20 639 21 298
Non-current liability 7 254 10 040 7 254 10 040
Current liability 13 385 11 258 13 385 11 258
20 639 21 298 20 639 21 298
* The expense is charged to profit and loss R15 million (2023: R11 million).

Cash-settled grants

Shareholders approved the Share Incentive Scheme (Scheme) on 13 April 2010. Over time, various share grants and options were issued to directors and employees of the Company.

The purpose of the share incentive scheme is to serve as an incentive and reward to employees (including executive directors) of the Company and its subsidiary for services rendered and to be rendered, aimed at promoting the continued growth of the Company by giving employees an opportunity to acquire shares in the Company and to serve as a retention mechanism for employees whose services are regarded by the Company to be crucial to the future growth and sustainability of the Company's business. The Board grants share options and share grants on the recommendation of the Remuneration Committee.

0.6 million share grants (2023: 1.1 million) were forfeited due to performance conditions not being met.

The Monte Carlo option pricing model was used to determine the fair value of the share grants.

The vesting of the grants is based solely on performance measured based on two conditions: 50% based on Merafe's total shareholder return (TSR) and 50% based on HEPS growth.

If Merafe's TSR over the three years places it in one of the top four positions, then 50% of the number of performance shares granted (TSR Portion) will vest in equal proportions on the 3rd, 4th and 5th anniversaries of their grant. If Merafe's TSR over the three years places it in 6th position, then one-third of the TSR Portion will vest in equal proportions on the 3rd, 4th and 5th anniversaries of their grant. If Merafe's performance over the three years lies between any of the above points, then a prorated number of the TSR Portion will vest in equal proportions on the 3rd, 4th and 5th anniversaries of their grant. No share grants will vest for positions seven and less.

Vesting of the other 50% of grant shares will be in accordance with the following policy as determined by the Board:

  • The performance shares allocated will be subject to performance against the growth in HEPS measure;
  • If performance meets or exceeds the target, ie CPI + 2% per annum over the performance period, 100% of shares will vest;
  • If performance is at the threshold, ie CPI + 1% per annum over the performance period, 50% of shares subject to this measure will vest;
  • For performance below the threshold, 0% of shares subject to this measure will vest; and
  • Linear vesting will take place between different performance milestones.

In terms of the rules of the Scheme, the Company retains the discretion and the right to settle awards through the issue of new shares or in cash. As at 31 December 2024, the Company may still issue 97 885 481 Merafe shares to settle any awards contemplated under the Scheme upon vesting.

Accordingly, the Company may still issue up to the maximum number of shares contemplated under the Scheme to settle any awards.

The following assumptions were used in the valuation model:

2024
2020 – 2024
share grants
2023
2019 – 2023
share grants
Risk-free rate 7.49% 7.97%
Expected volatility* 30.83% 36.88%
Expected dividend yield 6.89% 8.28%
Expected life (years) 0.25 to 4.25 0.25 to 4.25
Vesting periods (years) 3 to 5 3 to 5
Weighted average share price (Rand) R1.43 R1.27
Weighted average exercise price (Rand) R1.58 R1.36
Weighted average grant price (Rand) R0.3 to R1.85 R0.3 to R1.85
Weighted average option value (Rand) R1.07 R0.86
Performance conditions Yes Yes
Intrinsic value of shares R37.9 million R41.6 million
* The expected volatility of 30.83% (2023: 36.88%) is based on the historic volatility of the Merafe share price over the past five years.

The following share grants relating to employees and executive directors were outstanding at 31 December 2024:

Vesting date Number of shares Share grant date
1 April 2025 6 387 846 1 April 2020
1 April 2025 2 647 592 1 April 2021
1 April 2025 1 405 178 1 April 2022
1 April 2026 2 647 595 1 April 2021
1 April 2026 1 405 179 1 April 2022
1 April 2026 1 921 035 1 April 2023
1 April 2027 1 405 181 1 April 2022
1 April 2027 1 921 035 1 April 2023
1 April 2027 1 803 060 1 April 2024
1 April 2028 1 921 035 1 April 2023
1 April 2028 1 803 061 1 April 2024
1 April 2029 1 803 065 1 April 2024
27 070 862

The following share grants relating to executive directors were outstanding at 31 December 2024:

Vesting date Ms Z Matlala
Number of shares
Mr D Chocho
Number of shares
1 April 2025 3 904 904 1 685 363
1 April 2025 1 618 480 698 539
1 April 2025 709 641 324 299
1 April 2026 1 618 480 698 539
1 April 2026 709 641 324 299
1 April 2026 1 006 647 460 027
1 April 2027 709 641 324 299
1 April 2027 1 006 647 460 027
1 April 2027 910 671 461 946
1 April 2028 1 006 647 460 027
1 April 2028 910 671 461 946
1 April 2029 910 671 461 946
15 022 741 6 821 257

The movement in the number of share grants can be summarised as follows:

2024 
Number of 
shares 
2023 
Number of 
shares 
Opening balance  31 972 423  34 751 401 
Granted during the year  5 409 186  5 763 105 
Vested during the year  (9 673 090) (7 463 859)
Forfeited during the year  (637 657) (1 078 224)
Closing balance  27 070 862  31 972 423